Dodge & Cox 13F: Cuts Sanofi (SNY) Stake by $1.2B

Dodge & Cox recently trimmed its stake in Sanofi, trading on the NasdaqGS under the ticker SNY. According to its latest 13F filing with the SEC, the fund cut its position by 47.8%, selling off approximately 26.99 million shares. This reduction left Dodge & Cox with about 29.5 million shares, valued at $1.3 billion as of the reporting period.

What Changed in Dodge & Cox's Sanofi Position

Dodge & Cox significantly reduced its holdings in Sanofi, shedding nearly 27 million shares. Previously, the fund held around 56.5 million shares. After the reduction, it now holds approximately 29.5 million shares, marking a 47.8% decrease. This move reflects a substantial adjustment in its investment in the French pharmaceutical giant.

Sanofi Stock Up 4.2%

Shares of Sanofi (NasdaqGS: SNY) are trading around $44.11. The company boasts a market capitalization of $105.9 billion and a price-to-earnings ratio of 19.4. Sanofi's forward P/E is notably lower at 8.4, indicating expectations for future earnings growth. The stock's 52-week range spans from $42.28 to $52.68, with a 50-day moving average of $45.16 and a 200-day moving average of $47.31. Sanofi's beta of 0.275 suggests lower volatility compared to the broader market.

Recent Earnings

Sanofi reported revenues of approximately $47.35 billion, reflecting a 6% growth. The company achieved a net margin of 15.95% and a return on equity of 6.58%. Earnings per share stood at $2.28. Investors can look forward to the next earnings release on July 30, 2026.

Dividend

Sanofi offers a dividend rate of $2.42 per share, yielding 5.48% based on current prices. The dividend payout ratio is high at 97.7%, indicating that most of the company's earnings are returned to shareholders as dividends.

About Sanofi

Sanofi is a global healthcare leader headquartered in Paris, France. It focuses on the research, development, manufacturing, and marketing of therapeutic solutions. The company provides a variety of vaccines and treatments, covering areas such as immunology, neurology, oncology, and rare diseases. Sanofi is led by CEO Ms. Belen Garijo Lopez and employs around 74,846 people worldwide.

Bottom Line

Dodge & Cox's decision to cut its Sanofi stake by nearly half is a notable shift in its investment strategy. Investors often track such moves for insights into fund strategies, though it's important to remember that 13F filings are backward-looking and may not reflect current positions. Sanofi remains a significant player in the healthcare sector, offering a robust dividend yield and preparing for its next earnings report in late July.